GlobeNewswire (Wed, 4:15PM)
Cellectar Biosciences Announces Pricing of $12,500,000 Public Offering and Listing on The Nasdaq Capital MarketGlobeNewswire (Thu, 7:39PM)
Cellectar Biosciences Announces 1-for-20 Reverse Stock Split and Reduction in Authorized Shares of Common StockGlobeNewswire (Jun 13, 2014)
Cellectar Biosciences Announces Presentations at 2014 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire (May 30, 2014)
GlobeNewswire (May 29, 2014)
Today, 4:30 PM
Today, 4:18 PM
Mon, Aug. 11, 11:53 AM
- Cellectar Biosciences (OTCQX:CLRB) submits an IND seeking regulatory approval to begin the clinical study of the radiopharmaceutical I-131-CLR1404 for the treatment of relapsed/refractory multiple myeloma.
- President and CEO Dr. Simon Pedder says, "The radiosensitivity of multiple myeloma has been well-established and preclinical models show pronounced uptake of our phospholipid ether (PLE) analog delivery platform and significant therapeutic response to a single dose administration of I-131-CLR1404. We believe the selective nature and prolonged retention of our agent could enable effective, localized treatment to suppress or eliminate malignant plasma cells while preserving the important functions of normal blood cells."
Fri, Jun. 13, 10:33 AM
- Cellectar Biosciences (CLRB +8.6%) announces a 1:20 reverse split of its common stock effective at today's close of business. Post-split shares will begin trading Monday morning. The move will reduce the number of outstanding shares from ~57M to ~2.8M. The firm also decreases the number of authorized shares from 150M to 20M.
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.
CLRB vs. ETF Alternatives
Cellectar Biosciences Inc is a biopharmaceutical company. It is engaged in developing compounds for treatment and imaging of cancer. Its portfolio consists of PET imaging agents, optical imaging agents and therapeutic agents.
Other News & PR